See more : Kosmos Energy Ltd. (KOS) Income Statement Analysis – Financial Results
Complete financial analysis of IRadimed Corporation (IRMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IRadimed Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Compagnia Immobiliare Azionaria S.p.A. (CIA.MI) Income Statement Analysis – Financial Results
- KALIMETALS FPO [KM1] (KM1.AX) Income Statement Analysis – Financial Results
- Dongguan Chitwing Technology Co., Ltd. (002855.SZ) Income Statement Analysis – Financial Results
- InterPrivate III Financial Partners Inc. (IPVF-UN) Income Statement Analysis – Financial Results
- Sejal Glass Limited (SEZAL.NS) Income Statement Analysis – Financial Results
IRadimed Corporation (IRMD)
About IRadimed Corporation
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical support representatives, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.56M | 53.30M | 41.81M | 31.72M | 38.52M | 30.44M | 23.08M | 32.50M | 31.59M | 15.65M | 11.34M | 7.69M |
| Cost of Revenue | 15.40M | 12.02M | 9.76M | 8.14M | 8.82M | 7.21M | 5.57M | 6.15M | 5.84M | 3.40M | 2.85M | 2.13M |
| Gross Profit | 50.16M | 41.28M | 32.05M | 23.57M | 29.70M | 23.23M | 17.51M | 26.34M | 25.75M | 12.25M | 8.49M | 5.56M |
| Gross Profit Ratio | 76.50% | 77.45% | 76.65% | 74.33% | 77.11% | 76.31% | 75.87% | 81.06% | 81.51% | 78.25% | 74.84% | 72.34% |
| Research & Development | 2.86M | 2.28M | 1.91M | 1.90M | 1.43M | 1.52M | 1.72M | 1.35M | 1.76M | 1.07M | 1.01M | 654.07K |
| General & Administrative | 15.12M | 10.70M | 9.77M | 12.27M | 10.45M | 8.71M | 9.00M | 8.80M | 7.77M | 4.82M | 2.39M | 1.55M |
| Selling & Marketing | 12.14M | 12.68M | 10.56M | 10.16M | 9.17M | 7.00M | 5.50M | 5.28M | 4.71M | 3.30M | 2.30M | 1.93M |
| SG&A | 27.26M | 23.38M | 20.33M | 22.43M | 19.62M | 15.71M | 14.50M | 14.07M | 12.48M | 8.11M | 4.69M | 3.48M |
| Other Expenses | 0.00 | 553.10K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Operating Expenses | 30.12M | 25.65M | 22.23M | 24.33M | 21.05M | 17.22M | 16.23M | 15.42M | 14.24M | 9.18M | 5.70M | 4.13M |
| Cost & Expenses | 45.53M | 37.68M | 32.00M | 32.47M | 29.87M | 24.44M | 21.80M | 21.58M | 20.08M | 12.59M | 8.55M | 6.26M |
| Interest Income | 1.86M | 581.85K | 34.81K | 132.19K | 388.80K | 238.11K | 122.58K | 126.42K | 148.91K | 5.70K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 581.85K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 765.18K | 670.67K | 634.01K | 603.60K | 591.18K | 559.73K | 445.27K | 248.30K | 223.94K | 149.06K | 139.04K | 106.28K |
| EBITDA | 20.80M | 16.30M | 11.22M | 582.73K | 9.89M | 7.11M | 2.59M | 11.17M | 11.51M | 3.21M | 2.93M | 1.53M |
| EBITDA Ratio | 31.73% | 29.32% | 26.84% | 1.84% | 25.68% | 23.35% | 11.24% | 34.37% | 37.15% | 20.54% | 25.80% | 19.92% |
| Operating Income | 20.04M | 15.63M | 9.82M | -756.09K | 8.65M | 6.00M | 1.29M | 10.92M | 11.51M | 3.07M | 2.79M | 1.42M |
| Operating Income Ratio | 30.56% | 29.32% | 23.48% | -2.38% | 22.45% | 19.72% | 5.57% | 33.60% | 36.44% | 19.59% | 24.58% | 18.54% |
| Total Other Income/Expenses | 1.70M | 553.10K | 18.61K | 139.21K | 395.91K | 193.54K | 111.38K | 32.68K | 121.39K | -48.55K | -3.46K | 7.42K |
| Income Before Tax | 21.74M | 16.18M | 9.84M | -616.88K | 9.04M | 6.20M | 1.40M | 10.95M | 11.63M | 3.02M | 2.78M | 1.43M |
| Income Before Tax Ratio | 33.16% | 30.36% | 23.52% | -1.94% | 23.48% | 20.36% | 6.05% | 33.70% | 36.83% | 19.28% | 24.55% | 18.63% |
| Income Tax Expense | 4.55M | 3.35M | 510.82K | -1.99M | -587.64K | -106.14K | 896.62K | 3.74M | 4.10M | 966.98K | 846.88K | 465.98K |
| Net Income | 17.19M | 12.83M | 9.33M | 1.37M | 9.63M | 6.30M | 499.76K | 7.21M | 7.53M | 2.05M | 1.94M | 966.09K |
| Net Income Ratio | 26.22% | 24.07% | 22.30% | 4.32% | 25.00% | 20.71% | 2.17% | 22.20% | 23.83% | 13.10% | 17.08% | 12.57% |
| EPS | 1.36 | 1.02 | 0.76 | 0.11 | 0.85 | 0.52 | 0.05 | 0.67 | 0.68 | 0.23 | 0.19 | 0.09 |
| EPS Diluted | 1.35 | 1.02 | 0.74 | 0.11 | 0.78 | 0.52 | 0.04 | 0.60 | 0.60 | 0.20 | 0.19 | 0.09 |
| Weighted Avg Shares Out | 12.60M | 12.56M | 12.35M | 12.12M | 11.28M | 12.11M | 10.64M | 10.82M | 11.00M | 8.74M | 10.42M | 10.42M |
| Weighted Avg Shares Out (Dil) | 12.72M | 12.64M | 12.59M | 12.44M | 12.28M | 12.11M | 11.72M | 11.99M | 12.56M | 10.22M | 10.42M | 10.42M |
iRadimed (IRMD) is on the Move, Here's Why the Trend Could be Sustainable
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
IRADIMED CORPORATION Named to Fortune's 100 Fastest Growing Companies List for 2024
WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune's 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”)...
IRADIMED CORPORATION (IRMD) Q3 2024 Earnings Call Transcript
IRADIMED CORPORATION. (NASDAQ:IRMD ) Q3 2024 Earnings Conference Call October 31, 2024 11:00 AM ET Company Participants Roger Susi - President and Chief Executive Officer Jack Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Jason...
IRadimed (IRMD) Beats Q3 Earnings and Revenue Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.43 per share a year ago.
IRADIMED CORPORATION Announces Third Quarter of 2024 Financial Results and the Declaration of its Regular Quarterly Cash Dividend of $0.15 Per Share
WINTER SPRINGS, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) announced today its financial results for the three and nine months ended September 30, 2024. The Company is a leader in the development of innovative magnetic resonance...
IRADIMED CORPORATION to Hold 2024 Third Quarter Financial Results Conference Call on October 31st
WINTER SPRINGS, Fla., Oct. 24, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2024 third quarter financial results before the market opens on Thursday, October 31, 2024. Iradimed management will host a...
IRADIMED CORPORATION to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
WINTER SPRINGS, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that it will participate in the 3rd Annual ROTH Healthcare Opportunities Conference.
IRADIMED CORPORATION To Participate in the Lake St. Annual Best Ideas Growth “Big 8” Investor Conference
WINTER SPRINGS, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announced today that the Company will be participating in the Lake Street 8 th...
IRADIMED CORPORATION (IRMD) Q2 2024 Earnings Call Transcript
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2024 Results Conference Call August 1, 2024 12:00 PM ET Company Participants Roger Susi - President and Chief Executive Officer Matt Garner - Controller Conference Call Participants Frank Takkinen - Lake Street Capital Jason Wittes...
IRadimed (IRMD) Surpasses Q2 Earnings and Revenue Estimates
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.36 per share a year ago.
Source: https://incomestatements.info
Category: Stock Reports